Stock 603229 ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Zhejiang Ausun Pharmaceutical Co., Ltd.

Equities

603229

CNE100002XK2

Pharmaceuticals

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-25 pm EDT 		5-day change 1st Jan Change
10.49 CNY +0.87% Intraday chart for Zhejiang Ausun Pharmaceutical Co., Ltd. +9.84% -20.59%
Apr. 26 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Apr. 26 Zhejiang Ausun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Capitalization 1 8,765 10,451 9,564 7,834 6,221 -
Enterprise Value (EV) 1 8,765 10,451 9,564 7,834 6,221 6,221
P/E ratio 93.9 x 71.4 x 40.3 x 30.7 x 16 x 12 x
Yield 0.2% 0.28% - 0.98% 1.81% 2.29%
Capitalization / Revenue 21.4 x 18.3 x 12.5 x 9.59 x 5.34 x 4.14 x
EV / Revenue 21.4 x 18.3 x 12.5 x 9.59 x 5.34 x 4.14 x
EV / EBITDA - 55 x 32.7 x 23.7 x 13.2 x 9.53 x
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book 7.78 x 8.33 x 6.55 x 3.66 x 2.79 x 2.41 x
Nbr of stocks (in thousands) 562,613 562,613 562,613 593,069 593,069 -
Reference price 2 15.58 18.58 17.00 13.21 10.49 10.49
Announcement Date 4/27/21 4/19/22 4/27/23 4/26/24 - -
1CNY in Million2CNY
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net sales 1 409.2 569.7 764.5 816.8 1,164 1,501
EBITDA 1 - 190.2 292.2 331.2 471 653
EBIT 1 96.61 160.2 257.7 290.8 422 563
Operating Margin 23.61% 28.11% 33.71% 35.61% 36.24% 37.51%
Earnings before Tax (EBT) 1 95.5 159.4 255.9 290.8 420.5 562
Net income 1 86.84 145.9 235.4 253.9 387 516.5
Net margin 21.22% 25.62% 30.79% 31.09% 33.23% 34.41%
EPS 2 0.1658 0.2602 0.4214 0.4300 0.6550 0.8750
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share 2 0.0319 0.0520 - 0.1290 0.1900 0.2400
Announcement Date 4/27/21 4/19/22 4/27/23 4/26/24 - -
1CNY in Million2CNY
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) 12.7% 12.3% 17.4% 12.7% 18.3% 21%
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 2.000 2.230 2.600 3.610 3.760 4.360
Cash Flow per Share 2 0.2500 0.3100 0.2100 0.3700 0.5500 0.7000
Capex 1 92.9 311 272 163 37 37
Capex / Sales 22.71% 54.53% 35.54% 19.99% 3.18% 2.47%
Announcement Date 4/27/21 4/19/22 4/27/23 4/26/24 - -
1CNY in Million2CNY
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Zhejiang Ausun Pharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.49
Average target price
-
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
ZHEJIANG AUSUN PHARMACEUTICAL CO., LTD. Stock Zhejiang Ausun Pharmaceutical Co., Ltd.
-20.59% 859M
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.83% 661B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+27.00% 566B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.76% 352B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.34% 332B
ABBVIE INC. Stock AbbVie Inc.
+3.00% 283B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.09% 231B
NOVARTIS AG Stock Novartis AG
+5.46% 200B
ROCHE HOLDING AG Stock Roche Holding AG
-9.61% 195B
AMGEN INC. Stock Amgen Inc.
-6.26% 145B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. 603229 Stock
  4. Financials Zhejiang Ausun Pharmaceutical Co., Ltd.